Single institution experience looking at efficacy of PD-1 inhibitors after progression on PD-L1 inhibitors or vice-versa in metastatic non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e21726
Abstract: e21726Background: The treatment landscape for metastatic NSCLC has changed dramatically with emergence of checkpoint inhibitors (CPI). Even though all currently approved CPI target engagement of PD... read more here.
Keywords: looking efficacy; institution experience; efficacy inhibitors; inhibitors progression ... See more keywords